Trial
NCT01769196
Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF)
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Gilead Sciences
Collaborators
—
Condition
Idiopathic Pulmonary Fibrosis
Intervention
Simtuzumab
Why stopped
The Study was terminated due to lack of efficacy.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-05-30